DTx Pharma in the news

DTx Pharma announces acquisition by Novartis

DTx Pharma Receives FDA Orphan Drug Designation for DTx-1252 for the Treatment of Charcot-Marie-Tooth Disease Type 1A (CMT1A)

The Medicine Maker | Flying with the FALCON: An inside view on a platform that could help take RNA therapeutics to the next level of delivery